NGUALA STEVE

Dr. NGUALA STEVE

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2022 in Microorganisms
Verified
Journal Article
Open access
PDF file
ARAlice Raffetin
Alice Raffetin
JSJulien Schemoul
Julien Schemoul
CAchahour amal
chahour amal
NSNGUALA STEVE
NGUALA STEVE
PPPAULINE CARAUX PAZ
PAULINE CARAUX PAZ
OGon the behalf of the Tick-Borne Diseases Reference Center-Paris and Northern Region Working Group
on the behalf of the Tick-Borne Diseases Reference Center-Paris and Northern Region Working Group
Introduction. Because patients with a suspicion of Lyme borreliosis (LB) may have experienced difficult care paths, the Tick-Borne Diseases Reference Center (TBD-RC) was started in 2017. The aim of our study was to compare the clinical features of patients according to their final diagnoses, and to determine the factors associated with recovery in the context of multidisciplinary management for suspected LB. Methods. We included all adult patients who were seen at the TBD-RC (2017–2020). Four groups were defined: (i) confirmed LB, (ii) possible LB, (iii) Post-Treatment Lyme Disease Syndrome (PTLDS) or sequelae, and (iv) other diagnoses. Their clinical evolution at 3, 6, and 9–12 months after care was compared. Factors associated with recovery at 3 and at 9–12 months were identified using logistic regression models. Results. Among the 569 patients who consulted, 72 (12.6%) had confirmed LB, 43 (7.6%) possible LB, 58 (10.2%) PTLDS/sequelae, and 396 (69.2%) another diagnosis. A favorable evolution was observed in 389/569 (68.4%) at three months and in 459/569 (80.7%) at 12 months, independent of the final diagnosis. A longer delay between the first symptoms and the first consultation at the TBD-RC (p = 0.001), the multiplicity of the diagnoses (p = 0.004), and the inappropriate prescription of long-term antibiotic therapy (p = 0.023) were negatively associated with recovery, reflecting serial misdiagnoses. Conclusions. A multidisciplinary team dedicated to suspicion of LB may achieve a more precise diagnosis and better patient-centered medical support in the adapted clinical sector with a shorter delay, enabling clinical improvement and avoiding inappropriate antimicrobial prescription.

31 July 2021 in Pathogens
Verified
Journal Article
Open access
PDF file
NSNGUALA STEVE
NGUALA STEVE
EBElisabeth Baux
Elisabeth Baux
SPSolène Patrat-Delon
Solène Patrat-Delon
FSFlorian Saunier
Florian Saunier
JSJulien Schemoul
Julien Schemoul
ARAlice Raffetin
Alice Raffetin
Background: Most European and American countries recently updated their guidelines on Lyme borreliosis (LB). The aim of this study was to provide a comparative overview of existing guidelines on the treatment of LB in Europe and America and to assess the methodological quality of their elaboration. Methods: A systematic search was carried out in MEDLINE, Google Scholar, and the national databases of scientific societies from 2014 to 2020. Quality was assessed by two independent reviewers using the Appraisal of Guidelines for Research and Evaluation II (AGREE II) tool. Results: Twelve guidelines were included. The scores for the AGREE II domains (median ± IQR) were: overall assessment 100 ± 22, scope and purpose 85 ± 46, stakeholder involvement 88 ± 48, rigour of development 67 ± 35, clarity of presentation 81 ± 36, applicability 73 ± 52 and editorial independence 79% ± 54%. Cohen’s weighted kappa showed a high agreement (K = 0.90, 95%CI 0.84–0.96). Guidelines were quite homogeneous regarding the recommended molecules (mostly doxycycline in the first intention and ceftriaxone in the second intention), their duration (10 to 28 days), and their dosage. The differences were due to the lack of well-conducted comparative trials. The International Lyme and Associated Diseases Society (ILADS) guidelines were the only ones to suggest longer antibiotics based on an expert consensus. Conclusion: European and American guidelines for the treatment of LB were quite homogeneous but based on moderate- to low-evidence studies. Well-conducted comparative trials are needed to assess the best molecules, the optimal duration and the most effective doses.

15 July 2021 in Microorganisms
Verified
Journal Article
Open access
PDF file
ARAlice Raffetin
Alice Raffetin
ABAude Barquin
Aude Barquin
NSNGUALA STEVE
NGUALA STEVE
GPGiulia Paoletti
Giulia Paoletti
CRChristian Rabaud
Christian Rabaud
HPHenri Partouche
Henri Partouche
Background: Some subjective symptoms may be reported at all stages of Lyme borreliosis (LB) and may persist for several months after treatment. Nonspecific symptoms without any objective manifestation of LB are sometimes attributed by patients to a possible tick bite. The aim of our study was to explore the perceptions, representations, and experiences that these patients had of their disease and care paths. Methods: We performed a qualitative study through individual interviews (October 2017–May 2018), based on grounded theory, following the COREQ checklist. A balanced sample of patients with diverse profiles was recruited at consultations with general practitioners and infectious disease physicians. Results: Twelve patients were interviewed. Data saturation was reached at the twelfth interview. For codes, 293 were identified, and classified into 5 themes: (1) the experience of disabling nonspecific symptoms, especially pain, causing confusion and fear, (2) long and difficult care paths for the majority of the patients, experienced as an obstacle course, (3) a break with the previous state of health, causing a negative impact on every sphere of the patient’s life, (4) empowerment of the patients and the self-management of their disease, and (5) the strong expression of a desire for change, with better listening, greater recognition of the symptoms, and simpler care paths. Conclusions: This study allows for the understanding of a patient’s behaviours and the obstacles encountered, the way they are perceived, and the necessary solutions. The patients’ expectations identified here could help physicians better understand the doctor–patient relationship in these complex management situations, which would reduce the burden of the disease. The current development of specialised reference centres could help meet the patients’ demands and those of family physicians.

28 November 2025 in Infectious Diseases Now
Verified
Journal Article
Closed access
EBElisabeth Baux
Elisabeth Baux
YHYves Hansmann
Yves Hansmann
CTChristine Tranchant
Christine Tranchant
FRFrance Roblot
France Roblot
PAPauline Arias
Pauline Arias
ARAlice Raffetin
Alice Raffetin

26 November 2025 in Infectious Diseases Now
Verified
Journal Article
Closed access
PAP. Arias
P. Arias
XGxavier gocko
xavier gocko
FRF. Roblot
F. Roblot
YHY. Hansmann
Y. Hansmann
EBElisabeth Baux
Elisabeth Baux
ARAlice Raffetin
Alice Raffetin

1 August 2021 in Infectious Diseases Now
Verified
Journal Article
Closed access
SMS. de Monteynard
S. de Monteynard
NSNGUALA STEVE
NGUALA STEVE
DJD. Jaafar
D. Jaafar
ABA. Bounhiol
A. Bounhiol
PPPAULINE CARAUX PAZ
PAULINE CARAUX PAZ
ABA. Belkacem
A. Belkacem